UNCERTAIN TRANSLATION, UNCERTAIN BENEFIT AND UNCERTAIN RISK: ETHICAL CHALLENGES FACING FIRST-IN-HUMAN TRIALS OF INDUCED PLURIPOTENT STEM (IPS) CELLS

The discovery of induced pluripotent stem (iPS) cells in 2006 was heralded as a major breakthrough in stem cell research. Since then, progress in iPS cell technology has paved the way towards clinical application, particularly cell replacement therapy, which has refueled debate on the ethics of stem...

Full description

Saved in:  
Bibliographic Details
Authors: Fung, Ronald K. F. (Author) ; Kerridge, Ian H. (Author)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Interlibrary Loan:Interlibrary Loan for the Fachinformationsdienste (Specialized Information Services in Germany)
Published: 2013
In: Bioethics
Year: 2013, Volume: 27, Issue: 2, Pages: 89-96
Further subjects:B Stem Cells
B Risk
B first-in-human trials
B Parkinson's Disease
B research ethics
Online Access: Presumably Free Access
Volltext (lizenzpflichtig)
Volltext (lizenzpflichtig)

MARC

LEADER 00000caa a22000002c 4500
001 1781884331
003 DE-627
005 20230426163123.0
007 cr uuu---uuuuu
008 211211s2013 xx |||||o 00| ||eng c
024 7 |a 10.1111/j.1467-8519.2011.01896.x  |2 doi 
035 |a (DE-627)1781884331 
035 |a (DE-599)KXP1781884331 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Fung, Ronald K. F.  |e VerfasserIn  |4 aut 
245 1 0 |a UNCERTAIN TRANSLATION, UNCERTAIN BENEFIT AND UNCERTAIN RISK: ETHICAL CHALLENGES FACING FIRST-IN-HUMAN TRIALS OF INDUCED PLURIPOTENT STEM (IPS) CELLS 
264 1 |c 2013 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a The discovery of induced pluripotent stem (iPS) cells in 2006 was heralded as a major breakthrough in stem cell research. Since then, progress in iPS cell technology has paved the way towards clinical application, particularly cell replacement therapy, which has refueled debate on the ethics of stem cell research. However, much of the discourse has focused on questions of moral status and potentiality, overlooking the ethical issues which are introduced by the clinical testing of iPS cell replacement therapy. First-in-human trials, in particular, raise a number of ethical concerns including informed consent, subject recruitment and harm minimisation as well as the inherent uncertainty and risks which are involved in testing medical procedures on humans for the first time. These issues, while a feature of any human research, become more complex in the case of iPS cell therapy, given the seriousness of the potential risks, the unreliability of available animal models, the vulnerability of the target patient group, and the high stakes of such an intensely public area of science. Our paper will present a detailed case study of iPS cell replacement therapy for Parkinson's disease to highlight these broader ethical and epistemological concerns. If we accept that iPS cell technology is fraught with challenges which go far beyond merely refuting the potentiality of the stem cell line, we conclude that iPS cell research should not replace, but proceed alongside embryonic and adult somatic stem cell research to promote cross-fertilisation of knowledge and better clinical outcomes. 
601 |a Translation 
601 |a Challenger 
650 4 |a Risk 
650 4 |a Parkinson's Disease 
650 4 |a Stem Cells 
650 4 |a first-in-human trials 
650 4 |a research ethics 
700 1 |a Kerridge, Ian H.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Bioethics  |d Oxford [u.a.] : Wiley-Blackwell, 1987  |g 27(2013), 2, Seite 89-96  |h Online-Ressource  |w (DE-627)271596708  |w (DE-600)1480658-7  |w (DE-576)078707986  |x 1467-8519  |7 nnas 
773 1 8 |g volume:27  |g year:2013  |g number:2  |g pages:89-96 
856 |u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1467-8519.2011.01896.x  |x unpaywall  |z Vermutlich kostenfreier Zugang  |h publisher [deprecated] 
856 4 0 |u https://doi.org/10.1111/j.1467-8519.2011.01896.x  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1467-8519.2011.01896.x  |x Verlag  |z lizenzpflichtig  |3 Volltext 
935 |a mteo 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 4019007314 
LOK |0 003 DE-627 
LOK |0 004 1781884331 
LOK |0 005 20211211042817 
LOK |0 008 211211||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2021-12-10#3E01EE0DD693F04AEE85F99F9F7C07F95FC6A592 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 935   |a ixzs  |a ixrk  |a zota 
OAS |a 1 
ORI |a SA-MARC-ixtheoa001.raw